官方APP下载:英语全能特训(微信小程序版,支持苹果手机、安卓手机)
创办于2003年
UNSV记不住?那就记中文谐音“忧安思危”吧!
  Slow and Steady Wins the Race!
UNSV英语学习频道 - Slow and steady wins the race!
公众微信服务号
英语全能特训(微信公众服务号)
UNSV英语学习频道淘宝网店
客服短信:18913948480
客服邮箱:web@unsv.com
初级VIP会员
全站英语学习资料下载。
¥98元/12个月

Eli Lilly Seeks Approval for Experimental COVID-19 Antibody Drug

阅读次数:


VIP会员专享下载:(非VIP会员无权下载!如果想下载,但还不是VIP会员,请点此订购
下载方式:使用鼠标右键(注意是鼠标右键!)点击下面的MP3音频/MP4视频链接,然后选择“另存为…”。
MP3节目录音 MP3节目录音 
文章原文
同步字幕

Drug maker Eli Lilly and Company said Wednesday it has asked U.S. officials to approve emergency use of an experimental antibody treatment for COVID-19.

Lilly said early results of a study show the treatment reduced hospital emergency room visits for persons with mild or moderate forms of COVID-19. It said the therapy also reduced signs of the disease, the amount of the virus and length of hospital stays for such patients.

The company announced the study's partial results before a meeting with investors and the public. The findings have yet to be published or examined by independent scientists.

The antibody treatment appears to work like one given to President Donald Trump last Friday. The treatment he took was developed by Regeneron Pharmaceuticals.

Both therapies are designed to connect human antibodies to the coronavirus that causes COVID-19 and limit its ability to spread. The antibodies are usually given as a one-time treatment through intravenous therapy.

FILE - In this May 2020 photo provided by Eli Lilly, a researcher tests possible COVID-19 antibodies in a laboratory in Indianapolis. (David Morrison/Eli Lilly via AP, File)
FILE - In this May 2020 photo provided by Eli Lilly, a researcher tests possible COVID-19 antibodies in a laboratory in Indianapolis. (David Morrison/Eli Lilly via AP, File)

Daniel Skovronsky is a doctor and Eli Lilly's chief scientific officer. He said in a statement, 'We believe the data generated to date provide sufficient evidence that both monotherapy and combination therapy may be effective to treat COVID-19 in patients with a high risk for serious outcomes."

The monotherapy involves an antibody called LY-CoV555. The combination therapy combines that antibody with an antibody called LY-CoV016.

The medical news website StatNews reported that "Lilly had previously released results for a similar treatment using one antibody, which experts viewed as promising. But the new results, of a combination of two antibodies, appear, based on limited data provided in a press release, to be more robust."

The drug maker is asking the U.S. Food and Drug Administration (FDA) to permit use of its single antibody treatment in emergency situations. The company expects to seek government approval of the combination treatment in November.

At this time, the FDA has only approved the drug remdesivir for emergency use in COVID-19 patients. The president's personal doctor confirmed that Trump has also started a five-day treatment of remdesivir.

Lilly said it has already started manufacturing the drug LY-CoV555. The company expects to have 100,000 doses ready in October and 1 million by the end of the year. It hopes to have 50,000 doses of the combination therapy ready by year's end.

The drug maker added that it is also "working with regulators around the world to make these treatments available.'

I'm Jonathan Evans.

Hai Do wrote this story for Learning English. George Grow was the editor.

Words in This Story

intravenous - adj. through a vein

monotherapy - n. the use of a single drug to treat a disease or condition

outcome - n. something that happens as a result of an activity or process

view - v. to think about something in a particular way

robust - adj. strongly formed

dose - n. the amount of medicine

regulator - n. a government official who controls the public activity by making and enforcing rules

网友的学习评论(0条):
版权所有©2003-2019 南京通享科技有限公司,保留所有权利。未经书面许可,严禁转载本站内容,违者追究法律责任。 互联网经营ICP证:苏B2-20120186
网站备案:苏公网安备 32010202011039号苏ICP备05000269号-1中国工业和信息化部网站备案查询
广播台